Denifanstat 52-Week Acne Data Shows Durable Efficacy, Clean Safety Ahead of U.S. Phase 3
SGMT has more than doubled off its 52-week low of $4.5.
Summary
Sagimet's license partner Ascletis presented full 52-week open-label extension results for denifanstat in moderate-to-severe acne at EADV 2026. The data show treatment success in 56.7% of patients, with total lesion counts down 71.8% and inflammatory lesions down 76.9% from baseline. Safety was clean: no drug-related serious adverse events, no discontinuations due to adverse events, and only dry skin (7.1%) and dry eye (5.9%) exceeding 5% incidence. This is the first detailed look at long-term denifanstat data and directly de-risks the upcoming U.S. AURORA Phase 3 trial, which begins patient screening in October. The results reinforce the drug's profile as a potential first-in-class oral acne therapy, a market with ~10 million U.S. patients. The KOL call later today will provide additional color, but the data itself is a meaningful positive for the stock. Sagimet terminated its at-the-market offering prospectus supplement effective September 30, 2026.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Sagimet terminated its at-the-market offering prospectus supplement effective September 30, 2026.
At the time of this announcement, SGMT was trading at $9.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $574.6M. The 52-week trading range was $4.50 to $11.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.